Use of long-acting muscarinic antagonists for severe asthma: insights from clinicians in the SHARP network.

ABSTRACT:

Background

There is limited real-world evidence on the use and positioning of inhaled long-acting muscarinic antagonists (LAMAs) for treating severe asthma.

Objective

We aimed to assess the differences in clinicians' perspectives on prescribing LAMA for severe asthma across Europe.

Methods

Within the Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) network, we conducted a multi-country survey of 470 respiratory clinicians in 2023-24.

Results

Most participants were pneumonologists (83%). 68% reported using specific criteria for prescribing LAMA for severe asthma, primarily fixed bronchial obstruction (68%), frequent asthma exacerbations (65%), and a history of smoking (53%). Improved quality of life, lung function improvement, and redu

SUBMITTER: Marcon A 

PROVIDER: S-EPMC12584430 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature